psmafore: methodology, nuances, and implications
Published 9 months ago • 88 plays • Length 6:53Download video MP4
Download video MP3
Similar videos
-
10:20
psmafore results: [177lu]lu-psma-617 in taxane-naive patients with mcrpc
-
3:56
peace-1: identifying prognostic and predictive biomarkers for soc treatment of mcspc
-
7:39
psmafore phase 3 study
-
7:14
vision study
-
10:47
therap trial
-
14:05
lutetium 177 psma - problems with the vision trial
-
1:10:05
psma scans & pluvicto (lutetium-177) in 2022 | geoffrey johnson, md, phd | pcri conference 2022
-
40:03
psma & lutetium-177 in 2022 | eugene kwon, md | diy combat manual for beating prostate cancer part 4
-
36:15
information session: targeting the potential of psma
-
11:08
psma in metastatic prostate cancer: imaging as biomarker
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
1:24
luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer
-
1:39
secure: 67cu-sar-bispsma, a novel psma theranostic, in mcrpc
-
4:40
prostate specific antigen (psa) | overview for med students | urology
-
1:09:07
episode 111: refining psma testing in prostate cancer: next-generation imaging strategies
-
1:52
lesson 3. understanding neoplasm nomenclature
-
6:57
understanding prostate cancer
-
1:34
lu-psma-617 deployment and future of prostate cancer treatment
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
0:57
dr. meng discusses the significance of mri-us fusion targeted biopsies in prostate cancer
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc